Importance

Loading Importance Indicators...

Abstract

In an aspect, the invention provides methods and uses of PCAT18 for diagnosing, prognosing, and treatment monitoring of prostate cancer (PCa) in a subject. In another aspect, methods of treating PCa in a subject by administering an inhibiting agent of PCAT18 are provided. Uses of PCAT18 in treating PCa in a subject, and pharmaceutical compositions comprising a therapeutic agent effective to reduce the amount of PCAT18 in cancerous prostate cells and a pharmaceutically acceptable carrier, are also provided. The transcript of PCAT18 is a long non-coding RNA (lncRNA), whose expression is significantly altered in biological samples obtained from subjects with PCa or at risk of developing PCa compared to normal individuals. Expression of PCAT18 is specific to prostate tissue and is elevated in both cancerous prostate tissue and blood plasma of subjects with PCa relative to subjects without PCa or patients with other forms of cancer.

Loading the Abstract Image...

First Claim